+612 9045 4394
 
CHECKOUT
ANCA-Associated Vasculitides : Immunological and Clinical Aspects - Wolfgang L. Gross

ANCA-Associated Vasculitides

Immunological and Clinical Aspects

By: Wolfgang L. Gross (Editor)

Hardcover Published: 30th November 1993
ISBN: 9780306445736
Number Of Pages: 552

Share This Book:

Hardcover

RRP $1099.99
$761.25
31%
OFF
or 4 easy payments of $190.31 with Learn more
Ships in 7 to 10 business days

Other Available Editions (Hide)

WEGENER'S GRANULOMATOSIS & ANCA-ASSOCIATED DISEASES: THE STORY CONTINUES The disease now designated as Wegener's granulomatosis (WG) was first described in 1931 by Heinz Klinger, who considered it to be a special form of polyarteritis nodosa. Klinger's friend, Friedrich Wegener, expanded on the first observations and interpreted the pathological and clinical fmdings to represent a distinct disease entity (Wegener, 1939). He described this entity as a "peculiar rhinogenous granulomatosis with a unique participation of the arterial system and the kidneys". Later, Godman and Churg (1954) established the classical diagnostic criteria (the "WG triad"): granuloma, vasculitis, and glomerulonephritis. In 1958 Walton pointed out the poor prognosis of WG based on a small number of published cases (mean survival time: 5 months). In 1966 Carrington and Liebow reported "limited forms" of WG with a defmitely more favorable prognosis. Since then positive results have been reported with cyclophosphamide therapy. In addition, a retrospective study of combined low-dose cyclophosphamide and prednisolone in 85 WG patients over a period of 21 years found a similarly encouraging outcome. TheĀ·latter experience led to the current "standard" treatment protocol (FAUCI et al. , 1973 and 1983). More recently, strong evidence has emerged that some of the morbidity and mortality ofWG - and other types of systemic vasculitis - may be a consequence of this treatment (Hoffman et al. , 1992).

Friedrich Wegener and the Nature of Famep. 1
Pathogenic Potential of Anti-Neutrophil Cytoplasmic Autoantibodiesp. 7
Neutrophilic Leukocyte Granules: From Structure to Functionp. 17
Pathogenic Aspects of Autoantibodies to Endothelial Cells in Systemic Vasculitisp. 35
Membrane Surface Proteinase 3 Expression and Intracytoplasmic Immunoglobulin on Neutrophils from Patients with ANCA-Associated Vasculitidesp. 45
A New Approach to the Molecular Characterization of the c-ANCA Antigen in Wegener's Granulomatosisp. 51
Proteinase 3: Substrate Specificity and Possible Pathogenetic Effect of Wegener's Granulomatosis Autoantibodies (c-ANCA) by Dysregulation of the Enzymep. 55
Inhibition of Proteinase 3 Activity by Peptides Derived from Human Epidermisp. 61
Implications of c-ANCA Testing for the Classification of Wegener's Granulomatosis: Performance of Different Detection Systemsp. 65
ANCA and IgG Subclassesp. 71
Anti-MPO Antibody (Id) and Autoantibody to Purified Anti-MPO F(Ab)2 (Anti-Id)p. 77
Cross-Reactivity between Antibodies to Thyroid Microsomal Antigens and Myeloperoxidasep. 81
Antineutrophil Cytoplasmic Autoantibodies (ANCA) Recognizing a Recombinant Myeloperoxidase Subunitp. 87
Pooled Human IgG (PHIG) Inhibits the Binding of Anti-Myeloperoxidase Antibodies to Myeloperoxidasep. 93
Studies to Demonstrate Inhibition of Functional Activity of Neutrophil Lysosomal Enzymes with ANCAp. 97
Lactoferrin Co-Purifies with Myeloperoxidase and is Recognised by Anti-Neutrophil Cytoplasm Antibodiesp. 101
ANCA Specificities for HL-60 and Neutrophil Constituentsp. 105
In Vitro Interactions of c-ANCA (Antibodies to Proteinase 3) with Human Endothelial Cellsp. 109
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Increase Neutrophil Adhesion to Cultured Human Endotheliump. 115
Myeloperoxidase Binds to Vascular Endothelial Cells, is Recognized by ANCA and Can Enhance Complement Dependent Cytotoxicityp. 121
Vascular Permeability Changes Induced by Antibodies to Myeloperoxidasep. 125
Endothelium Myeloperoxidase, Anti-Myeloperoxidase Interaction in Vasculitisp. 129
Further Characterization of an Animal Model of Systemic Vasculitisp. 133
Induction of a Humoral and Cellular (Auto) Immune Response to Human and Rat Myeloperoxidase (MPO) in Brown-Norway (BN), Lewis and Wistar Kyoto (WKY) Rat Strainsp. 139
Disease Associations with Anti-Neutrophil Cytoplasmic Antibodiesp. 145
Classification of Vasculitisp. 157
Classification of Systemic Vasculitis - A Pathologist's Viewp. 165
Polyarteritis Nodosa and Churg-Strauss Syndrome - An Internist's Viewp. 173
Vasculitis from the Rheumatologist's Viewpointp. 185
A Nephrological View of the Classification of Vasculitisp. 197
The Nosology of Wegener's Granulomatosis Utilizing the Elk Format Augmented by c-ANCAp. 209
Vasculitis - The Neurologist's Viewp. 217
Treatment of Chronic Idiopathic Systemic Vasculitidesp. 227
Monoclonal Antibody Therapy for Vasculitisp. 235
Heterogeneity of ANCA Sera Showing Atypical, Peripheral and Classical Cytoplasmic Immunofluorescence Patternsp. 239
ANCA in Systemic Vasculitides, Collagen Vascular Diseases, Rheumatic Disorders and Inflammatory Bowel Diseasesp. 245
Perinuclear Antineutrophil Cytoplasmic Antibodies (P-ANCA): Clinical Significance and Relation to Antibodies against Myeloid Lysosomal Enzymesp. 253
Methods of Detection of Anticathepsin G Autoantibodies in Humanp. 257
Anti-Myeloperoxidase Antibodies and Associated Diseasesp. 263
Autoantibodies Directed against Lysozyme: A New Target Antigen for Anti-Neutrophil Cytoplasmic Antibodies (ANCA)p. 267
Clinical Significance of ANCA in 98 Patientsp. 273
Anti-Neutrophil Cytoplasmic Autoantibodies (ANCA): Antigenic Specificities and Clinical Associationsp. 281
Significance of Autoantibodies to Purified Proteinase 3 in Systemic Vasculitisp. 287
Characterization Anti-Myeloperoxidase Antibodies in Vasculitisp. 291
Low Predictive Value of c-ANCA and Anti-[alpha]-Granule Antibody for Vasculitis in Hong Kongp. 295
Detection and Clinical Associations of Autoantibodies to Myeloid Granular Proteinsp. 299
Relationship between Disease Activity and ANCA Level by ELISA in the Long-Term Management of Vasculitisp. 303
ANCA in Ocular Inflammatory Disordersp. 305
Head and Neck Involvement in Wegener's Granulomatosis (WG)p. 309
Orbital Involvement in Wegener's Granulomatosisp. 315
MRI of the Head in Wegener's Granulomatosisp. 319
The Clinical, Serologic, and Immunopathologic Heterogeneity of Cutaneous Leukocytoclastic Angiitisp. 323
No ANCA in Thromboangiitis Obliterans (Burger's Disease)p. 327
Alpha-1-Proteinase Inhibitor and Pulmonary Haemorrhage in Systemic Vasculitisp. 331
Alpha-1-Antitrypsin, CRP and Interleukin-6 in ANCA-Positive Vasculitisp. 337
Pro- and Anti-Inflammatory Cytokines in Primary Systemic Vasculitisp. 341
Problems of Classification in Necrotizing Vasculitisp. 345
Anti-Neutrophil Cytoplasm Antibodies in HIV Infectionsp. 349
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) and Infectionp. 353
Anti-Lactoferrin Antibodies in Patients with Rheumatoid Arthritis with Vasculitisp. 357
Anti-Neutrophil Cytoplasmic Antibodies in Giant Cell Arteritis and Polymyalgia Rheumaticap. 363
Antibodies to Neutrophil Cytoplasmic Antigens in Rheumatoid Arthritisp. 367
Incidence and Specificity of p-ANCA in Rheumatic Diseasesp. 371
Anti-Granulocyte Perinuclear Antibodies but not Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Rheumatoid Arthritisp. 375
Anti-Neutrophil Cytoplasmic Antibodies in Patients with Systemic Lupus Erythematosusp. 381
ANCA with Specificity for Lactoferrin in Systemic Lupus Erythematosus (SLE)p. 385
Serum Markers of T-Cell Activation in Relapses of Wegener's Granulomatosisp. 389
Presence of Anticardiolipin Antibodies Discriminates between Wegener's Granulomatosis and Microscopic Polyarteritisp. 393
Increased Expression of CD25 and Adhesion Molecules on Peripheral Blood Lymphocytes of Patients with Wegener's Granulomatosis (WG) and ANCA Positive Vasculitidesp. 397
Wegener's Granulomatosis with Severe Peripheral and Central Neuropathy - Case Reportp. 405
Limited Prognostic Value of Changes in Antineutrophil Cytoplasmic Antibody Titers in Patients with Wegener's Granulomatosisp. 411
Wegener's Granulomatosis and Henoch-Schonlein Purpura in a Family with Hereditary C4 Deficiencyp. 415
Little Evidence for Anti-Endothelial-Cell Antibodies in Microscopic Polyarteritis and Wegener's Granulomatosisp. 419
Prevalence of ANCAs in Patients on Maintenance Haemodialysisp. 423
Rhabdomyolysis in Vasculitisp. 427
Rapidly Progressive Glomerulonephritis (RPGN): Is There Still an "Idiopathic" Subgroup?p. 431
Association between Silica Exposure and Necrotizing Crescentic Glomerulonephritis with p-ANCA and anti-MPO Antibodies: A Hospital-Based Case-Control Studyp. 435
ANCA and Anti-GBM Antibodies in RPGNp. 441
p-ANCA with Myeloperoxidase Antibodies and c-ANCA with Proteinase 3 Antibodies Define a Different Vasculitis Entity in Patients with Renal Involvementp. 445
Antineutrophil-Cytoplasmic-Autoantibodies in Poststreptococcal Nephritisp. 449
Identification of Apparent Dual ANCA Specificities in a Subset of Patients with Systemic Vasculitis and Crescentic Glomerulonephritisp. 455
c-ANCA and p-ANCA Positive Vasculitis with Crescentic Glomerulonephritis: The Same Clinical Feature but Different Immunological Pathways?p. 461
Clinical Manifestations in Patients on Chronic dialysis with High Titres of ANCAp. 465
Pooled Intravenous Immunoglobulin in the Management of Systemic Vasculitisp. 469
Cyclosporin A Therapy for Wegener's Granulomatosisp. 473
Necrotizing Vasculitis - Relapse Despite Cytotoxic Therapyp. 477
Effectiveness of Cyclophosphamide Pulse Treatment in Wegener's Granulomatosisp. 483
Treatment of Wegener's Granulomatosis with Intravenous Immunoglobinp. 487
Treatment of Wegener's Granulomatosisp. 491
Treatment Modalities and ANCA in Takayasu's Arteritisp. 497
Late Recurrence of Systemic Vasculitis after Kidney Transplantation Involving the Kidney Allograftp. 503
P-ANCA of Undefined Specificity in Ulcerative Colitis: Correlation to Disease Activity and Therapyp. 507
Anti-Neutrophil cytoplasmic Auto-Antibodies (ANCA) in Patients with Ulcerative Colitis (UC): Influence of Disease Activity and Familial Studyp. 515
Antineutrophil Antibodies in Inflammatory Bowel Disease Recognize Different Antigensp. 519
Anti-Neutrophil Cytoplasmic Auto-Antibodies in Sera from Patients with Ulcerative Colitis after Proctocolectomy with Ileo-Anal Anastomosisp. 523
p-ANCA as a Diagnostic Marker in Ulcerative Colitisp. 527
Lactoferrin, Anti-Lactoferrin Antibodies and Inflammatory Diseasep. 533
Detection of Antineutrophil Cytoplasmic Antibodies (ANCA) and their Association with Other Autoantibodies in Patients with Hepatobiliary Disordersp. 539
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in Autoimmune Liver Diseasep. 545
Indexp. 551
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9780306445736
ISBN-10: 0306445735
Series: Advances in Experimental Medicine and Biology
Audience: Professional
Format: Hardcover
Language: English
Number Of Pages: 552
Published: 30th November 1993
Publisher: Springer Science+Business Media
Country of Publication: US
Dimensions (cm): 23.4 x 15.6  x 3.18
Weight (kg): 2.16